Harbour Antibodies, the creator of transgenic mice to aid in the development of new human therapeutic antibodies, announced today that it has licensed its H2L2 mice, which can generate human monoclonal antibodies, to Pfizer Inc.
Harbour Antibodies’ transgenic H2L2 mice enable biotechs, pharmaceutical companies and academic research labs to speed new drug development by generating human antibodies using traditional hybridoma technology. Under the licensing agreement, Pfizer will have the option to use the mice in as many projects as they wish without disclosing the nature of the projects to Harbour.
This licensing deal marks the third partnership for Harbour Antibodies. Previous deals have been announced involving the H2L2 mice with Eli Lilly and Company and ChemPartner Co.
Harbour Antibodies is enabling the development of new therapeutic human monoclonal antibodies through the creation of two lines of transgenic mice. The are the H2L2 mice, which generate full IgG and the HCAb mice, which generate heavy chain only human antibodies. Both lines are currently available for licensing.